Skip to main content

Advertisement

Log in

Long-Term Effectiveness of Azathioprine in IBD Beyond 4 Years: A European Multicenter Study in 1176 Patients

  • Original Paper
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

In Crohn’s disease the optimal duration of azathioprine treatment is still controversial and for ulcerative colitis only limited data are available to support its efficacy. Charts of 1176 patients with IBD from 16 European centers were analyzed. Flare incidences and steroid dosages were assessed for the time before and during treatment and after discontinuation. Within the first 4 years, azathioprine suppressed flare incidence and steroid consumption in both diseases (P < 0.001). While in CD discontinuation after 3–4 years did not lead to reactivation, this was the case in UC. However, continuation beyond 4 years further improved clinical activity in CD and steroid requirement in both diseases (P < 0.001). Discontinuation of azathioprine may thus be considered after 3–4 years in CD patients in complete remission without steroid requirement. In all other CD patients and for UC patients in general, continuation seems beneficial. These results support a novel differential algorithm for long-term azathioprine therapy in IBD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C (2000) Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease. Cochrane Database Syst Rev 2:CD000545

    PubMed  Google Scholar 

  2. Pearson DC, May GR, Fick G, Sutherland LR (2000) Azathioprine for maintaining remission of Crohn’s disease. Chochrane Database Syst Rev

  3. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R (1995) A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut 5:674–678

    Article  Google Scholar 

  4. Bouhnik Y, Lemann M, Mary JY, Scemama G, Tai R, Matuchansky C, Modigliani R, Rambaud JC (1996) Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Lancet 347:215–219

    Google Scholar 

  5. Kim PS, Zlatanic J, Korelitz BI, Gleim GW (1999) Optimum duration of treatment with 6-mercaptopurine for Crohn’s disease. Am J Gastroenterol 11:3254–3257

    Google Scholar 

  6. Kirk AP, Lennard-Jones JE (1982) Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J 1291–1292

  7. Rosenberg JL, Wall AJ, Levin B, Binder HJ, Kirsner JB (1975) A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 1:96–99

    Google Scholar 

  8. Jewell DP, Truelove SC (1974) Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J 5945:627–630

    Google Scholar 

  9. Hawthorne AB, Logan RF, Hawkey CJ, Foster PN, Axon AT, Swarbrick ET, Scott BB, Lennard-Jones JE (1992) Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. Br Med J 6844:20–22

    Article  Google Scholar 

  10. Ardizzone S, Molteni P, Imbesi V, Bollani S, Bianchi Porro G, Molteni F (1997) Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol 330–333

  11. Theodor E, Niv Y, Bat L (1981) Imuran in the treatment of ulcerative colitis. Am J Gastroenterol 262–266

  12. Steinhart AH, Baker JP, Brzezinski A, et al. (1990) Azathioprine therapy in chronic ulcerative colitis. J Clin Gastroenterol 271–275

  13. Fraser AG, Orchard TR, Jewell DP (2002) The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 485–489

  14. Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, Lehr HA, Wirtz S, Becker C, Atreya R, Mudter J, Hildner K, Bartsch B, Holtmann M, Blumberg R, Walczak H, Iven H, Galle P, Ahmadian MR (2003) CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 1133–1145

  15. Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Feigl S, Yang Z, Exley M, Kitani A, Blumberg RS, Mannon P, Strober W (2004) Nonclassical CD1d-restricted NK T cells that produced IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 1490–1497

  16. Neurath MF, Finotto S, Glimcher LH (2002) The role of Th1/Th2 polarization in mucosal immunity. Nat Med 6:567–573

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Markus F. Neurath.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Holtmann, M.H., Krummenauer, F., Claas, C. et al. Long-Term Effectiveness of Azathioprine in IBD Beyond 4 Years: A European Multicenter Study in 1176 Patients. Dig Dis Sci 51, 1516–1524 (2006). https://doi.org/10.1007/s10620-005-9037-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-005-9037-5

Keywords

Navigation